TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05683717: A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies

Sponsor: TransThera Sciences (Nanjing), Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 37 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT05683717 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05683717 Rescue Dossier →